Clinical Report: Ferroptosis-Immune Interactions in CNS Disorders

Overview

Ferroptosis, an iron-dependent form of regulated cell death, plays a critical role in modulating immune responses in central nervous system (CNS) disorders. This bidirectional interplay between ferroptosis and immune activation contributes to neuroinflammation, neuronal loss, and tumor immunity, presenting novel therapeutic opportunities.

Background

Ferroptosis is characterized by iron-driven lipid peroxidation leading to cell death, significantly impacting neurons and glial cells in CNS diseases. Immune cells, including microglia and T cells, interact with ferroptotic pathways, influencing disease progression in neurodegenerative disorders such as Alzheimer's, Parkinson's, and ALS, as well as in gliomas. Dysregulated iron metabolism and oxidative stress create a feedback loop that exacerbates neuroinflammation and tissue damage. Understanding the ferroptosis-immune axis is essential for developing targeted interventions in CNS pathologies.

Data Highlights

Key molecular players include iron transporters (TfR1, DMT1), antioxidant systems (glutathione, GPX4), and immune mediators (TNF-α, IL-1β, IFN-γ). Pro-inflammatory cytokines upregulate neuronal iron uptake, promoting ferroptosis, while ferroptotic cell products further activate immune responses. In glioma, CD8+ T cell-derived IFN-γ induces ferroptosis by suppressing SLC7A11, enhancing anti-tumor immunity. Therapeutic strategies involve small molecules, immunomodulators, and nanotechnology targeting this axis.

Key Findings

• Ferroptosis is driven by iron-dependent lipid peroxidation and ROS accumulation, leading to neuronal and glial cell death.
• Activated microglia release pro-inflammatory cytokines (TNF-α, IL-1β) that increase neuronal iron uptake via transporters like DMT1 and TfR1, promoting ferroptosis.
• Ferroptotic cells release damage-associated molecular patterns that amplify immune activation, creating a self-perpetuating neuroinflammatory cycle.
• In gliomas, CD8+ T cell-derived IFN-γ suppresses SLC7A11 in tumor cells, depleting glutathione and inactivating GPX4, thereby inducing ferroptosis and modulating anti-tumor immunity.
• Therapeutic targeting of the ferroptosis-immune interface shows promise in mitigating neurodegeneration and enhancing anti-tumor responses.
• Challenges remain in understanding cell type-specific ferroptosis susceptibilities and the spatiotemporal dynamics of ferroptosis-immune crosstalk in vivo.

Clinical Implications

Targeting ferroptosis and its interaction with immune pathways offers a novel approach to treat CNS disorders by reducing neuroinflammation and neuronal loss or enhancing anti-tumor immunity. Clinicians should consider the ferroptosis-immune axis when developing or applying therapies for neurodegenerative diseases and brain tumors. Future treatments may combine ferroptosis inhibitors or inducers with immunomodulatory agents for improved efficacy.

Conclusion

The ferroptosis-immune axis is a critical driver of CNS disease progression and represents a promising therapeutic target. Continued research into its mechanisms will enable precise interventions to mitigate neurological damage and improve patient outcomes.

References

1. Interplay of Ferroptosis and Immune Responses in CNS Disorders, 2024 -- Interactions Between Ferroptosis and Immune Responses in Central Nervous System Disorders: Mechanisms and Clinical Implications